Safe and effective air purification proven by over 15 years on the market and the most extensive safety and efficacy data in the industry.
Pyure efficacy was evaluated on five biosecurity level one (BSL-1) microorganisms that are considered representative of a broader range of more pathogenic organisms:
Select pathogen to view study results
Comparative Biosciences, Inc. in compliance with the US Food & Drug Administration GLP regulations (21 CFR Part 58), conducted a 13-week toxicity study on the effects of elevated Pyure output levels on a statistically significant population of rats. Rat exposure levels were 2 to 3 times higher than the maximum levels recommended by Pyure. The results showed no adverse effects on treated animals vs. control animals after continuous exposure for 13 weeks, neither at the gross or cellular level.
This toxicity study, along with the mechanism of action and pathogen destruction studies, were submitted to the FDA as part of the 510k registration and listing for the Odorox® MDU/Rx™ unit. As part of the FDA submission, a review of NIH, CDC and other relevant government databases was conducted. The review did not reveal any data or evidence that natural natural or artificial hydroxyls are in any way toxic to humans, animals or plants.
The study examined the chemistry that resulted from hydroxyl decomposition of volatile organic compounds (VOC). The study revealed that operating a Pyure device significantly reduced total VOC levels, resulting in better indoor air quality. The VOC were rapidly decomposed and the steady state amounts of intermediate organic compounds, including formaldehyde, other aldehydes, ketones and alcohols did not accumulate while the Pyure device was running. The study detected very low levels of ozone (less than 15 parts per billion), far below the 50 part-per-billion maximum established by the FDA for continuous exposure. The study confirmed that Pyure Technology improves indoor air quality.